New biweekly combination of trastuzumab, docetaxel, and gemcitabine for HER2-positive metastatic breast cancer: First early results from a phase II multicentric trial on behalf of Gruppo Oncologico Italia Meridionale

Category Primary study
JournalJournal of Clinical Oncology
Year 2009
This article has no abstract
Epistemonikos ID: 4b89c47f4ee319dd45f3bd722d5e0cb20fa8abf3
First added on: Mar 01, 2025